Drug Profile
AZD 6370
Alternative Names: AZD6370Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihyperglycaemics; Pyridines
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Jan 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Sweden (PO)
- 31 Jul 2008 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO)
- 31 Jul 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Sweden (PO)